Atherosclerosis
Volume 186, Issue 1 , Pages 29-37 , May 2006

Berberine inhibits rat vascular smooth muscle cell proliferation and migration in vitro and improves neointima formation after balloon injury in vivo: Berberine improves neointima formation in a rat model

  • Seahyoung Lee

      Affiliations

    • BK21 project of Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea
    • Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
    • ,
  • Hyun-Joung Lim

      Affiliations

    • Korea National Institute of Health, Department of Biomedical Sciences, 5 Nokbun-Dong, Enpyung-Gu, Seoul 122701, Republic of Korea
    • ,
  • Hyun-Young Park

      Affiliations

    • Korea National Institute of Health, Department of Biomedical Sciences, 5 Nokbun-Dong, Enpyung-Gu, Seoul 122701, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 380 1534; fax: +82 2 388 0924.
    • ,
  • Kuy-Sook Lee

      Affiliations

    • Korea National Institute of Health, Department of Biomedical Sciences, 5 Nokbun-Dong, Enpyung-Gu, Seoul 122701, Republic of Korea
    • ,
  • Jin-Hee Park

      Affiliations

    • Korea National Institute of Health, Department of Biomedical Sciences, 5 Nokbun-Dong, Enpyung-Gu, Seoul 122701, Republic of Korea
    • ,
  • Yangsoo Jang

      Affiliations

    • BK21 project of Medical Science, Yonsei University College of Medicine, Seoul, Republic of Korea
    • Yonsei Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul 120-752, Republic of Korea
    • Yonsei University Research Institute of Science for Aging, Yonsei University, Seoul, Republic of Korea
    • Corresponding Author InformationCorresponding author. Tel.: +82 2 361 7350; fax: +82 2 362 8647.

Received 31 January 2005 ,Revised 12 June 2005 ,Accepted 29 June 2005.

References 

  1. Amin AH, Subbaiah TV, Abbasi KM. Berberine sulfate: antimicrobial activity, bioassay, and mode of action. Can J Microbiol. 1969;15:1067–1076
  2. Rabbani GH, Butler T, Knight J, Sanyal SC, Alam K. Randomized controlled trial of berberine sulfate therapy for diarrhea due to enterotoxigenic Escherichia coli and Vibrio cholerae. J Infect Dis. 1987;155:979–984
  3. Subbaiah TV, Amin AH. Effect of berberine sulphate on Entamoeba histolytica. Nature. 1967;215:527–528
  4. Sun D, Courtney HS, Beachey EH. Berberine sulfate blocks adherence of Streptococcus pyogenes to epithelial cells, fibronectin, and hexadecane. Antimicrob Agents Chemother. 1988;32:1370–1374
  5. Kuo CL, Chi CW, Liu TY. The anti-inflammatory potential of berberine in vitro and in vivo. Cancer Lett. 2004;203:127–137
  6. Jantova S, Cipak L, Cernakova M, Kost’alova D. Effect of berberine on proliferation, cell cycle and apoptosis in HeLa and L1210 cells. J Pharm Pharmacol. 2003;55:1143–1149
  7. Anis KV, Rajeshkumar NV, Kuttan R. Inhibition of chemical carcinogenesis by berberine in rats and mice. J Pharm Pharmacol. 2001;53:763–768
  8. Pan GY, Huang ZJ, Wang GJ, et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 2003;69:632–636
  9. Leng SH, Lu FE, Xu LJ. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol Sin. 2004;25:496–502
  10. Yin J, Hu R, Chen M, et al. Effects of berberine on glucose metabolism in vitro. Metabolism. 2002;51:1439–1443
  11. Yang J, Zhou ZY, Xu JG. Protective effect of berberine on cardiac hypertrophy induced by L-thyroxine in rats. Sichuan Da Xue Xue Bao Yi Xue Ban. 2004;35:223–225
  12. Hong Y, Hui SS, Chan BT, Hou J. Effect of berberine on catecholamine levels in rats with experimental cardiac hypertrophy. Life Sci. 2003;72:2499–2507
  13. Hong Y, Hui SC, Chan TY, Hou JY. Effect of berberine on regression of pressure-overload induced cardiac hypertrophy in rats. Am J Chin Med. 2002;30:589–599
  14. Zheng L, Zhou Z, Tao D, Lan T. Protective effect of berberine on cardiac myocyte injured by ischemia-reperfusion. Sichuan Da Xue Xue Bao Yi Xue Ban. 2003;34:452–454
  15. Zeng XH, Zeng XJ, Li YY. Efficacy and safety of berberine for congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol. 2003;92:173–176
  16. Zhou LB, Chen MD, Wang X, et al. Effect of berberine on the differentiation of adipocyte. Zhonghua Yi Xue Za Zhi. 2003;83:338–340
  17. Lau CW, Yao XQ, Chen ZY, Ko WH, Huang Y. Cardiovascular actions of berberine. Cardiovasc Drug Rev. 2001;19:234–244
  18. Kong W, Wei J, Abidi P, et al. Berberine is a novel cholesterol-lowering drug working through a unique mechanism distinct from statins. Nat Med. 2004;10:1344–1351
  19. Lin S, Tsai SC, Lee CC, et al. Berberine inhibits HIF-1alpha expression via enhanced proteolysis. Mol Pharmacol. 2004;66:612–619
  20. Dimlich RV, Meineke HA, Reilly FD, McCuskey RS. The fluorescent staining of heparin in mast cells using berberine sulfate: compatibility with paraformaldehyde or o-phthalaldehyde induced fluorescence and metachromasia. Stain Technol. 1980;55:217–223
  21. Higashiyama S, Abraham JA, Klagsbrun M. Heparin-binding EGF-like growth factor stimulation of smooth muscle cell migration: dependence on interactions with cell surface heparan sulfate. J Cell Biol. 1993;122:933–940
  22. Asakura M, Kitakaze M, Takashima S, et al. Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med. 2002;8:35–40
  23. Inui H, Kitami Y, Kondo T, Inagami T. Transduction of mitogenic activity of platelet-derived growth factor (PDGF) AB by PDGF-beta receptor without participation of PDGF-alpha receptor in vascular smooth muscle cells. J Biol Chem. 1993;268:17045–17050
  24. Denker SP, Barber DL. Cell migration requires both ion translocation and cytoskeletal anchoring by the Na-H exchanger NHE1. J Cell Biol. 2002;159:1087–1096
  25. Redmond EM, Cahill PA, Hirsch M, et al. Effect of pulse pressure on vascular smooth muscle cell migration: the role of urokinase and matrix metalloproteinase. Thromb Haemost. 1999;81:293–300
  26. Kawamura M, Terashita Z, Okuda H, et al. TCV-116, a novel angiotensin II receptor antagonist, prevents intimal thickening and impairment of vascular function after carotid injury in rats. J Pharmacol Exp Ther. 1993;266:1664–1669
  27. Griendling KK, Ushio-Fukai M, Lassegue B, Alexander RW. Angiotensin II signaling in vascular smooth muscle. New concepts. Hypertension. 1997;29:366–373
  28. Li BX, Yang BF, Zhou J, Xu CQ, Li YR. Inhibitory effects of berberine on IK1, IK, and HERG channels of cardiac myocytes. Acta Pharmacol Sin. 2001;22:125–131
  29. Rouzaire-Dubois B, Dubois JM. K+ channel block-induced mammalian neuroblastoma cell swelling: a possible mechanism to influence proliferation. J Physiol. 1998;510(Pt. 1):93–102
  30. Eguchi S, Dempsey PJ, Frank GD, Motley ED, Inagami T. Activation of MAPKs by angiotensin II in vascular smooth muscle cells. Metalloprotease-dependent EGF receptor activation is required for activation of ERK and p38 MAPK but not for JNK. J Biol Chem. 2001;276:7957–7962
  31. Busse D, Doughty RS, Ramsey TT, et al. Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity. J Biol Chem. 2000;275:6987–6995
  32. Schlessinger J, Plotnikov AN, Ibrahimi OA, et al. Crystal structure of a ternary FGF-FGFR-heparin complex reveals a dual role for heparin in FGFR binding and dimerization. Mol Cell. 2000;6:743–750
  33. Yayon A, Klagsbrun M, Esko JD, Leder P, Ornitz DM. Cell surface, heparin-like molecules are required for binding of basic fibroblast growth factor to its high affinity receptor. Cell. 1991;64:841–848
  34. Gennaro G, Menard C, Michaud SE, Deblois D, Rivard A. Inhibition of vascular smooth muscle cell proliferation and neointimal formation in injured arteries by a novel, oral mitogen-activated protein kinase/extracellular signal-regulated kinase inhibitor. Circulation. 2004;110:3367–3371

PII: S0021-9150(05)00450-8

doi: 10.1016/j.atherosclerosis.2005.06.048

Atherosclerosis
Volume 186, Issue 1 , Pages 29-37 , May 2006

Article Tools

* Image Usage & Resolution